Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports

12-03-2024 | Aortic Valve Replacement | Valvular Heart Disease (TL Kiefer, Section Editor)

Cerebral Embolic Protection Devices for Transcatheter Aortic Valve Replacement: Review of the Literature and Future Perspectives

Authors: Spencer Ng, Taylor Cunningham, John P. Vavalle

Published in: Current Cardiology Reports

Login to get access

Abstract

Purpose of Review

Transcatheter aortic valve replacement (TAVR) has been a revolutionary therapy in the treatment of aortic valve stenosis. The risk of stroke associated with TAVR has decreased significantly since its introduction; however, it remains a devastating complication when it does occur.

Recent Findings

Many of the strokes associated with TAVR occur peri-procedurally and are thought to be due to embolic debris entering the cerebrovascular circulation. A number of different cerebral embolic protection devices (CEPD) have been developed and are in various stages of testing and use.

Summary

The results from clinical trials evaluating the role for CEPD to reduce the risk of stroke have been mixed. As a result, their uptake has been very heterogeneous. This review provides a summary of the diverse CEPD devices available for use and outlines the clinical evidence available to date.
Literature
1.
Mosaffarian D, Benjamin E, et al. Executive summary: heart disease and stroke statistics–2016 update: a report from the American Heart Association. Circulation. 2016;133:1483–8.
2.
3.
Leon M, Smith C, Mack M. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. New Eng J Med. 2010;263:1597–607.CrossRef
4.
Markham R, Sharma R. A review of the partner trials. Interv Cardiol Clin. 2020;9(4):461–7.PubMed
5.
Davlouros P, Mplani V, Koniari I, Tsigkas G. Transcatheter aortic valve replacement and stroke: a comprehensive review. J Geriatric Cardiol. 2018;15(1):95–104.
6.
Carroll J, Mack S, Vemulapalli S, et al. TS-ACC TVT registry of transcatheter aortic valve replacement. Ann Thoracic Surg. 2021;111(2):701–22.CrossRef
7.
Mack M, Leon M, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomized control trial. Lancet. 2015;9986:2477–84.CrossRef
8.
Perez-Carmargo D, Travieso A, Carnero-Alcazar M, Taramasso M, Cobiella-Carnicer J, et al. Neurological outcomes of transcatheter aortic valve implantation with or without cerebral embolic protection devices: a meta-analysis. J Stroke Cerebrovasc Dis. 2022;9:106605.CrossRef
9.
Kahlert P, Al-Rashid P, Dottger P. Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study. Circulation. 2012;126(10):1245–55.CrossRefPubMed
10.
Foley M, Hall K, Howard J, Ahmad Y, et al. Aortic valve calcium score is associated with acute stroke in transcatheter aortic valve replacement patients. J Soc Cardiovascular Angiogr Interv. 2022;4:100349.CrossRef
11.
Kahlert P, Knipp S, Schlamann M, Thielmann M, Al-Rashid F, Weber M. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: diffusion weighted magnetic resonance imaging study. Circulation. 2010;121(7):870–8.CrossRefPubMed
12.
•• Kapadia S, Makkar R, Leon M, Abdel-Wahab M, Waggoner T, Massberg S, et al. Cerebral embolic protection during transcatheter aortic-valve replacement. N Engl J Med. 2022;14:1253–63. This study showed that the use of the Sentinel CEPD in TAVR did not significantly decrease the incidence of stroke.CrossRef
13.
Fanning J, Walters D, Platts D, et al. Characterization of neurological injury in transcatheter aortic valve implantation: how clear is the picture? Circulation. 2014;129:504–15.CrossRefPubMed
14.
Thourani V, O’Brien S, Kelly J, et al. Development and application of a risk prediction model for in-hospital stroke after transcatheter aortic valve replacement: a report from the Society of Thoracic Surgeons/American College of Cardiology transcatheter valve therapy registry. Ann Thorac Surg. 2019;107:1097–103.CrossRefPubMed
15.
Van Mieghem N, Schipper M, Ladich E, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation. 2013;127:2194–201.CrossRefPubMed
16.
Gasior T, Mangner N, Bijoch J, Wojakowshi W. Cerebral embolic protection system for transcatheter aortic valve replacement. J Interv Cardiology. 2018;31:891–8.CrossRef
17.
Van Mieghem N, Van Gils L, Ahmad H, et al. Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial. Eur Interv. 2016;12:499–507.
18.
Haussig S, Mangener N, Dwyer M, et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis. The CLEAN-TAVI randomized clinical trial. JAMA. 2016;216:592–601.CrossRef
19.
• Kapadia S, Makkar R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol. 2017;69:367–77. This study showed that CEP devices are overall safe to use, but there was no significant difference in neurocognitive function in patients who had a CEP Devices versus those who did not at the time of TAVR implantation.CrossRefPubMed
20.
Demir O, Iannopollo G, Mangieri A, et al. The role of cerebral embolic protection devices during transcatheter aortic valve replacement. Front Cardiovasc Med. 2018;5:150.CrossRefPubMedPubMedCentral
21.
Samin M, van der Worp B, Agostoni P. TriGuardTM HDH embolic deflection device for cerebral protection during transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2017;89:470–7.CrossRef
22.
Baumbach A, Mullen M, Brickman A, et al. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. Eur Interv. 2015;11:75–84.
23.
Lansky A, Schofer J, Tchetche D, et al. A prospective randomized evaluation of the TriGuardTM HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J. 2015;36:2070–8.CrossRefPubMed
24.
Nazif T, Moses J, Sharma J, et al. Randomization of the evaluation of TriGuard cerebral embolic protection after transcatheter aortic valve replacement: REFLECT II. JACC Cardiovasc Interv. 2021;14:515–27.CrossRefPubMed
25.
Wendt D, Knipp S, et al. Intraaortic protection from embolization in patients undergoing transaortic transcatheter aortic calve implatation. Ann Thorac Surg. 2015;100:686–91.CrossRefPubMed
26.
Rodes-Cabau J, Kahlert P, Neumann F, Schymik G, Webb J, Amarenco P. Feasibility and exploratory efficacy evaluation of Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve repalcement: the PROTAVI-C pilot study. JACC Cardiovasc Interv. 2014;7(10):1146–55.CrossRefPubMed
27.
Russell S. Total embolic protection: the emboliner embolic protection catheter, early clinical results. Presented at Transcatheter Cardiovascular Therapeutics, San Francisco, California; 2019.
28.
Kolte D, Nazir S, Butala N, Bhatt D, Elmariah S. Trends in cerebral embolic protection device use and association with stroke following transcatheter aortic valve implantation. Am J Cardiol. 2021;152:106–12.CrossRefPubMed
29.
30.
Bagur R, Solo K, Alghofaili S, et al. Cerebral embolic protection devices during transcatheter aortic valve implantation. Systematic review and meta-analysis. Stroke. 2017;48:1306–15.CrossRefPubMed
31.
Rodes-Cabau J, Dumont E, Boone R, Larose E, Bagur R, Guvitch R. Cerebral ebolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. J Am Coll Cardiol. 2011;57(1):18–28.CrossRefPubMed
32.
Ghanem A, Dorner J, Schulze-Hagen L, Muller A, Wilsing M, Sinning J, et al. Subacute cubclinical brain infarctions after transcatheter aortic valve implantation negatively impact cognitive function in long-term follow-up. PLoS ONE. 2017;12(1):e0168852.CrossRefPubMedPubMedCentral
33.
Uddin A, Fairbairn T, Igra M, Djoukhader I. Consequences of cerebral embolism after transcatheteri aortic valve implantation compared with contemporary surgical valve replacement: effect on health-related quality of life. Circ Cardiovasc Interv. 2015;8(3):e001913.CrossRefPubMed
34.
Agrawal A, Isogai T, Shekhar S. Kapadia SR (2023) Cerebral embolic protection devices. US Cardiol Rev. 2023;17:e02.CrossRef
Metadata
Title
Cerebral Embolic Protection Devices for Transcatheter Aortic Valve Replacement: Review of the Literature and Future Perspectives
Authors
Spencer Ng
Taylor Cunningham
John P. Vavalle
Publication date
12-03-2024

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits